Plain-English translation of NCT06481566 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This clinical trial is testing whether almonertinib — a targeted medication designed to work against specific lung cancer mutations — works better when combined with stereotactic body radiotherapy (a precise, focused form of radiation). The study aims to see if this combination approach can help people with advanced non-small cell lung cancer live longer before their cancer progresses.
Standard treatments for advanced lung cancer don't always work long enough or well enough for all patients. Researchers believe that combining this targeted medication with focused radiation therapy early on might help keep the cancer under control for longer and improve outcomes.
You would start by taking the medication daily for 2 to 4 months. After that time, you would receive focused radiation therapy directed at any remaining lung tumors. Following radiation, you would continue taking the medication to maintain the treatment effect. Throughout the study, you would visit the hospital every 3 months for checkups, blood tests, and imaging scans, and you would keep a diary of any symptoms you experience.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
China